Johnson & Johnson JNJ

$253.79 -1.77 (-0.69%)

Valuation

Market cap
615,873,536,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.78
Forward PE
22.78
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,681,817
Avg volume
6,812,808
Day's range
$251.50 – $255.56
Shares out
2,409,898,000
Stochastic %K
54%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

HKLM93 Oct 19, 6:02 PM
$SLS 🤝 $JNJ
1 replies
SellasgpsCurativeBAT11 Oct 19, 5:08 PM
$ABBV $AZN $JNJ $PFE $SLS Dr. Stergiou At the May 19 Stifel presentation, CEO Angelos Stergiou said GPS was being administered to patients "even three years out at this point." At the May 27 Cowen oncology summit, he explained that treatment had been extended beyond the original one-year schedule, eventually beyond three years, at the request of physicians who assessed that their patients were benefiting. As a Biostatistician compelling reason to pay attention. Continued treatment years later, with physicians requesting the option to keep dosing, fits the possibility of durable benefit. ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Oct 19, 3:37 PM
$ABBV $AZN $JNJ $PFE $SLS $380 Billion in patent Expirations Big pharmaceuticals are very aggressive right now. Biotechnology sector is averaging 2 deals every week in 2026. 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 19, 3:27 PM
$ABBV $AZN $JNJ $PFE $SLS 9 trading days left in October 2026. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 19, 3:25 PM
$SLS $JNJ $PFE $ABBV $AZN Part 2. Timeline of events is condensed in a very short time frame now. Warrants extinguished the uptick will be very violent. $SLS Will trade over 100 million shares on the day GPS Regal Phase 3 Top line data is PR’d. $SLS won’t be a stand alone Co. after GPS Regal pivotal Registrational phase 3 data and will be part of a big pharmaceutical suitor. ✌️🙏❤️‍🩹
0 replies
Baddb Oct 19, 3:05 PM
$JNJ too many gaps below 😈
0 replies
chursinow62 Oct 19, 2:28 PM 0 replies
focafoca99 Oct 19, 12:34 PM
$JNJ highlighted new Phase 3 data showing TREMFYA achieves 35% fistula remission at 48 weeks in Crohn's disease. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-new-data-361133
0 replies